85 FR 161 pg. 51033 - Lead Exposure and Prevention Advisory Committee (LEPAC)
Type: NOTICEVolume: 85Number: 161Page: 51033
Page: 51033FR document: [FR Doc. 2020–18161 Filed 8–18–20; 8:45 am]
Agency: Health and Human Services Department
Sub Agency: Centers for Disease Control and Prevention
Official PDF Version: PDF Version
[top]
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Lead Exposure and Prevention Advisory Committee (LEPAC)
AGENCY:
Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).
ACTION:
Notice of meeting.
SUMMARY:
In accordance with the Federal Advisory Committee Act, the CDC announces the following meeting for the Lead Exposure and Prevention Advisory Committee (LEPAC). This meeting is open to the public by teleconference but advance registration by October 16, 2020 is needed to receive the information to join the meeting. The registration link is https://rossstrategic.zoom.us/webinar/register/WN_QsgX-UlJS02mWW8Kn8SUmg. The public comment period is scheduled on October 30, 2020 from 1:30 p.m. until 1:45 p.m. Individuals wishing to make a comment during the public comment period, please email your name, organization, and phone number by October 16, 2020 to LEPAC@cdc.gov.
DATES:
The meeting will be held on October 30, 2020, from 9:00 a.m. to 4:30 p.m., EDT.
ADDRESSES:
Register in advance at https://rossstrategic.zoom.us/webinar/register/WN_QsgX-UlJS02mWW8Kn8SUmg to receive information to join the meeting.
FOR FURTHER INFORMATION CONTACT:
Ms. Perri Ruckart, M.P.H., Designated Federal Officer, National Center for Environmental Health, CDC, 4770 Buford Highway, Atlanta, GA 30341, Telephone: 770-488-3300; email address pruckart@cdc.gov.
SUPPLEMENTARY INFORMATION:
Purpose: The Lead Exposure and Prevention Advisory Committee was established under Section 2203 of Public Law 114-322, the Water Infrastructure Improvements for the Nation Act; 42 U.S.C. 300j-27, Registry for Lead Exposure and Advisory Committee. The Secretary, Department of Health and Human Services (HHS) and by delegation, the Director, CDC and Administrator, NCEH/ATSDR, are authorized under Section 2203 of Public Law 114-322 (42 U.S.C. 300j-27) to review research and Federal programs and services related to lead poisoning and to identify effective services and best practices for addressing and preventing lead exposure in communities.
The LEPAC is charged with providing advice and guidance to the Secretary, HHS, and the Director, CDC and Administrator, ATSDR, on the: (1) Review of Federal programs and services available to individual communities exposed to lead; (2) review current research on lead exposure to identify additional research needs; (3) review and identify best practices, or the need for best practices regarding lead screening and the prevention of lead poisoning; (4) identify effective services, including services relating to healthcare, education, and nutrition for individuals and communities affected by lead exposure and lead poisoning, including in consultation with, as appropriate, the lead exposure registry as established in Section 2203(b) of Public Law 114-322; and (5) undertake any other review or activities that the Secretary determines to be appropriate.
Matters To Be Considered: The agenda will include discussions on the 2018 Federal Lead Action Plan; COVID-19 and CDC lead surveillance, lead laboratory methods; U.S. Housing and Urban Development's (HUD) role in lead poisoning prevention; an update from CDC's blood lead reference value workgroup; and a discussion on effective services and best practices regarding lead screening and lead poisoning prevention and research gaps. Agenda items are subject to change as priorities dictate. The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2020-18161 Filed 8-18-20; 8:45 am]
BILLING CODE 4163-18-P